|
|
№3 (приложение) / 2023
|
|
|
№10 (приложение) / 2022
|
|
Prokofieva T.V., Polunina O.S., Sevostianova I.V., Polunina E.A., Belyakova I.S., Perova N.Yu.
Levels of middle and low molecular weight substances in patients with Q-wave and without Q-wave myocardial infarction associated with chronic obstructive pulmonary disease
|
№10 / 2022
|
|
Suvorova N.A., Gordeev I.G., Luchinkina E.E.
Osteopontin in chronic obstructive pulmonary disease patients as a predictor of cardiovascular events
|
№9 / 2022
|
|
Sargsyan K.A., Stulin I.D. , Musin R.S., Malyavin A.G., Trukhanov S.A., Bekoeva Z.R., Seleznev F.A.
Cerebral venous discirculation in patients with chronic obstructive pulmonary disease in acute stage
|
№9 / 2022
|
|
Babak S.L., Gorbunova M.V., Goruleva E.I., Malyavin A.G.
Clinical life hacks in the treatment of acute bronchitis in post-covid patients with a new generation of phytodrugs BNO1201/1205
|
№7 / 2022
|
|
Prozorova G.G., Fateeva O.V., Tribuntseva L.V., Kozhevnikova S.A., Olysheva I.A.
Non-drug methods of treatment in pulmonology
|
№6 / 2022
|
|
Karoli N.A., Borodkin A.V., Rebrov A.P.
Risk factors for the development of adverse outcomes in patients with chronic obstructive pulmonary disease
|
№5 / 2022
|
|
Babkin A.P.
New diagnostic capabilities of the 6-minute walk test in COPD patients
|
№4 (приложение) / 2022
|
|
Babak S.L., Gorbunova M.V., Malyavin A.G.
Mucins and carbocisteine: respiratory protection
|
№10 / 2021
|
|
Shuginova T.N., Meldo A.A., Shaporova N.L., Moiseenko F.V., Klikunova K.A.
Pulmonary function test for chronic obstructive pulmonary disease patients with non-small cell lung cancer
|
№8 / 2021
|
|
Ignatova I.V., Blinova E.V., Antonov V.N.
Analysis of factors of poor outcome in patients with COPD and type 2 diabetes mellitus: results of a 10-year follow-up
|
№8 / 2021
|
Русский
